BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31570543)

  • 1. Overexpression of SLC12A5 is associated with tumor progression and poor survival in ovarian carcinoma.
    Yang GP; He WP; Tan JF; Yang ZX; Fan RR; Ma NF; Wang FW; Chen L; Li Y; Shen HW; You ZS; Xie D; Yang GF
    Int J Gynecol Cancer; 2019 Oct; 29(8):1280-1284. PubMed ID: 31570543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of Solute carrier family 12 member 5 via gene amplification contributes to tumour progression and metastasis and associates with poor survival in colorectal cancer.
    Xu L; Li X; Cai M; Chen J; Li X; Wu WK; Kang W; Tong J; To KF; Guan XY; Sung JJ; Chan FK; Yu J
    Gut; 2016 Apr; 65(4):635-46. PubMed ID: 25947013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma.
    Yang GF; Xie D; Liu JH; Luo JH; Li LJ; Hua WF; Wu HM; Kung HF; Zeng YX; Guan XY
    Gynecol Oncol; 2009 Feb; 112(2):314-8. PubMed ID: 19054548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss/Down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma.
    Yang G; He W; Cai M; Luo F; Kung H; Guan X; Zeng Y; Xie D
    Int J Gynecol Cancer; 2011 Apr; 21(3):486-93. PubMed ID: 21436696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma.
    Yang GF; He WP; Cai MY; He LR; Luo JH; Deng HX; Guan XY; Zeng MS; Zeng YX; Xie D
    BMC Cancer; 2010 Apr; 10():133. PubMed ID: 20377880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma.
    Lai B; Xiao Y; Pu H; Cao Q; Jing H; Liu X
    Arch Gynecol Obstet; 2012 May; 285(5):1455-61. PubMed ID: 22159627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
    Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
    Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
    Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
    Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-κB/MMP-7 signaling pathway.
    Liu JY; Dai YB; Li X; Cao K; Xie D; Tong ZT; Long Z; Xiao H; Chen MK; Ye YL; Liu B; Tan J; Tang J; Xu ZZ; Gan Y; Zhou YH; Deng F; He LY
    Cell Death Dis; 2017 Mar; 8(3):e2691. PubMed ID: 28333147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased expression of Beclin 1 correlates closely with Bcl-xL expression and poor prognosis of ovarian carcinoma.
    Lin HX; Qiu HJ; Zeng F; Rao HL; Yang GF; Kung HF; Zhu XF; Zeng YX; Cai MY; Xie D
    PLoS One; 2013; 8(4):e60516. PubMed ID: 23573264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma.
    He WP; Wang LL
    Oncol Lett; 2019 Nov; 18(5):4900-4906. PubMed ID: 31612000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Rossi E; Donzelli C; Todeschini P; Romani C; Bandiera E; Zanotti L; Carnazza M; Quadraro F; Tognon G; Sartori E; Pecorelli S; Roque DM; Santin AD
    J Transl Med; 2013 Jul; 11():162. PubMed ID: 23819652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.
    Ma RQ; Tang ZJ; Ye X; Cheng HY; Sun KK; Chang XH; Cui H
    Arch Gynecol Obstet; 2018 May; 297(5):1235-1244. PubMed ID: 29428978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of RFC3 is correlated with ovarian tumor development and poor prognosis.
    Shen H; Cai M; Zhao S; Wang H; Li M; Yao S; Jiang N
    Tumour Biol; 2014 Oct; 35(10):10259-66. PubMed ID: 25030735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage.
    Muller P; Coates PJ; Nenutil R; Trcka F; Hrstka R; Chovanec J; Brychtova V; Vojtesek B
    J Ovarian Res; 2019 Mar; 12(1):30. PubMed ID: 30917858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
    Zhang MZ; Qiao YH; Suo ZH
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
    Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
    BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.